

# Michel Kalamarides

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7678129/publications.pdf>

Version: 2024-02-01

75  
papers

3,213  
citations

147801

31  
h-index

161849

54  
g-index

79  
all docs

79  
docs citations

79  
times ranked

2971  
citing authors

#	ARTICLE	IF	CITATIONS
1	WHO grade II and III meningiomas: a study of prognostic factors. <i>Journal of Neuro-Oncology</i> , 2009, 95, 367-375.	2.9	284
2	High Incidence of Activating <i>TERT</i> Promoter Mutations in Meningiomas Undergoing Malignant Progression. <i>Brain Pathology</i> , 2014, 24, 184-189.	4.1	209
3	Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. <i>Genes and Development</i> , 2002, 16, 1060-1065.	5.9	201
4	Current treatment options for meningioma. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 241-249.	2.8	147
5	Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. <i>Oncogene</i> , 2011, 30, 2333-2344.	5.9	133
6	Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. <i>Oncogene</i> , 2009, 28, 854-865.	5.9	117
7	Meningiomas and neurofibromatosis. <i>Journal of Neuro-Oncology</i> , 2010, 99, 341-347.	2.9	113
8	Genomic Profiling Reveals Alternative Genetic Pathways of Meningioma Malignant Progression Dependent on the Underlying <i>NF2</i> Status. <i>Clinical Cancer Research</i> , 2010, 16, 4155-4164.	7.0	103
9	Surgery of the lateral skull base: a 50-year endeavour. <i>Acta Otorhinolaryngologica Italica</i> , 2019, 39, S1-S146.	1.5	91
10	Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. <i>Journal of Neuro-Oncology</i> , 2015, 122, 313-320.	2.9	87
11	Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. <i>Clinical Cancer Research</i> , 2020, 26, 552-557.	7.0	87
12	Associations of meningioma molecular subgroup and tumor recurrence. <i>Neuro-Oncology</i> , 2021, 23, 783-794.	1.2	83
13	Auditory Brainstem Implant in Neurofibromatosis Type 2 and Non-Neurofibromatosis Type 2 Patients. <i>Otology and Neurotology</i> , 2008, 29, 1140-1146.	1.3	79
14	Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. <i>Neuro-Oncology</i> , 2012, 14, 1090-1096.	1.2	72
15	mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. <i>Neuro-Oncology</i> , 2014, 16, 493-504.	1.2	67
16	Progestin-associated shift of meningioma mutational landscape. <i>Annals of Oncology</i> , 2018, 29, 681-686.	1.2	59
17	De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors. <i>Neuro-Oncology</i> , 2018, 20, 1113-1121.	1.2	56
18	Conserved meningeal lymphatic drainage circuits in mice and humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	54

#	ARTICLE	IF	CITATIONS
19	Somatic <i>PIK3CA</i> Mutations in Sporadic Cerebral Cavernous Malformations. <i>New England Journal of Medicine</i> , 2021, 385, 996-1004.	27.0	53
20	Four-Channel Electromyography of the Facial Nerve in Vestibular Schwannoma Surgery: Sensitivity and Prognostic Value for Short-Term Facial Function Outcome. <i>Otology and Neurotology</i> , 2005, 26, 114-120.	1.3	52
21	Intraoperative Electromyography and Surgical Observations as Predictive Factors of Facial Nerve Outcome in Vestibular Schwannoma Surgery. <i>Otology and Neurotology</i> , 2010, 31, 306-312.	1.3	52
22	<i>SMO</i> mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas. <i>Neuro-Oncology</i> , 2017, 19, now276.	1.2	49
23	Multivariate Analysis of Factors Influencing Facial Nerve Outcome following Microsurgical Resection of Vestibular Schwannoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 156, 525-533.	1.9	45
24	Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. <i>Annals of Oncology</i> , 2011, 22, 990-991.	1.2	44
25	Do Facial Nerve Displacement Pattern and Tumor Adhesion Influence the Facial Nerve Outcome in Vestibular Schwannoma Surgery?. <i>Otology and Neurotology</i> , 2009, 30, 392-397.	1.3	42
26	Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation. <i>Oncogene</i> , 2013, 32, 4264-4272.	5.9	41
27	Conservative Management of Bilateral Vestibular Schwannomas in Neurofibromatosis Type 2 Patients. <i>Neurosurgery</i> , 2013, 72, 907-914.	1.1	38
28	Hearing restoration with auditory brainstem implants after radiosurgery for neurofibromatosis Type 2. <i>Journal of Neurosurgery</i> , 2001, 95, 1028-1033.	1.6	35
29	PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with <i>Nf2</i> and <i>Cdkn2ab</i> loss. <i>Oncotarget</i> , 2015, 6, 32713-32722.	1.8	35
30	Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. <i>Neuro-Oncology</i> , 2021, 23, 1922-1935.	1.2	33
31	Natural History of Meningioma Development in Mice Reveals: A Synergy of Nf2 and p16Ink4a Mutations. <i>Brain Pathology</i> , 2008, 18, 62-70.	4.1	31
32	Functional outcome of retrosigmoid approach in vestibular schwannoma surgery. <i>Acta Oto-Laryngologica</i> , 2008, 128, 881-886.	0.9	31
33	Grade II meningiomas and Gamma Knife radiosurgery: analysis of success and failure to improve treatment paradigm. <i>Journal of Neurosurgery</i> , 2016, 125, 89-96.	1.6	31
34	Role of electrophysiology in guiding near-total resection for preservation of facial nerve function in the surgical treatment of large vestibular schwannomas. <i>Journal of Neurosurgery</i> , 2018, 128, 903-910.	1.6	29
35	Selective vulnerability of the primitive meningeal layer to prenatal Smo activation for skull base meningotheelial meningioma formation. <i>Oncogene</i> , 2018, 37, 4955-4963.	5.9	29
36	Continuous Facial Nerve Stimulating Burr for Otologic Surgeries. <i>Otology and Neurotology</i> , 2011, 32, 1347-1351.	1.3	28

#	ARTICLE	IF	CITATIONS
37	Processing of voices in deafness rehabilitation by auditory brainstem implant. <i>NeuroImage</i> , 2009, 47, 1792-1796.	4.2	27
38	Spinal ependymomas in NF2: a surgical disease?. <i>Journal of Neuro-Oncology</i> , 2018, 136, 605-611.	2.9	24
39	Meningioma mouse models. <i>Journal of Neuro-Oncology</i> , 2010, 99, 325-331.	2.9	23
40	Dramatic Shrinkage with Reduced Vascularization of Large Meningiomas After Cessation of Progestin Treatment. <i>World Neurosurgery</i> , 2017, 101, 814.e7-814.e10.	1.3	23
41	Molecular genetics of meningiomas: Building the roadmap towards personalized therapy. <i>Neurochirurgie</i> , 2018, 64, 22-28.	1.2	23
42	New insights into meningioma. <i>Current Opinion in Oncology</i> , 2012, 24, 660-665.	2.4	22
43	Use of bone anchoring device in electromagnetic computer-assisted navigation in lateral skull base surgery. <i>Acta Oto-Laryngologica</i> , 2013, 133, 1047-1052.	0.9	22
44	Posterior petrous bone meningiomas: surgical experience in 53 patients and literature review. <i>Neurosurgical Review</i> , 2012, 35, 53-66.	2.4	21
45	A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas. <i>Journal of Neuro-Oncology</i> , 2017, 133, 443-445.	2.9	21
46	Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports. <i>Neurochirurgie</i> , 2018, 64, 370-374.	1.2	21
47	ACTA OTORHINOLARYNGOLOGICA ITALICA. <i>Acta Otorhinolaryngologica Italica</i> , 2016, 36, 408-414.	1.5	20
48	Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1263-1273.	2.3	20
49	Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2. <i>Neuro-Oncology</i> , 2011, 13, 1125-1132.	1.2	19
50	Neurofibromatosis type 2: Hearing preservation and rehabilitation. <i>Neurochirurgie</i> , 2018, 64, 348-354.	1.2	15
51	Internal Auditory Canal Decompression for Hearing Maintenance in Neurofibromatosis Type 2 Patients. <i>Neurosurgery</i> , 2016, 79, 370-377.	1.1	14
52	How to radiologically identify a spontaneous regression of sporadic vestibular schwannoma?. <i>PLoS ONE</i> , 2019, 14, e0217752.	2.5	13
53	Natural history of vestibular schwannomas and hearing loss in NF2 patients. <i>Neurochirurgie</i> , 2018, 64, 342-347.	1.2	12
54	Improving facial nerve outcome and hearing preservation by different degrees of vestibular schwannoma resection guided by intraoperative facial nerve electromyography. <i>Acta Neurochirurgica</i> , 2020, 162, 1983-1993.	1.7	12

#	ARTICLE	IF	CITATIONS
55	Mouse Models in Meningioma Research: A Systematic Review. <i>Cancers</i> , 2021, 13, 3712.	3.7	11
56	Clinical response associated with radiographic regression of a cervicomedullary ependymoma in a NF2 patient treated by bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015, 125, 445-446.	2.9	10
57	Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study. <i>Neuro-Oncology</i> , 2021, 23, 1139-1147.	1.2	10
58	Auditory Brainstem Implant (Nucleus 21-Channel) in Neurofibromatosis Type 2 Patients Previously Operated on: Preliminary Results. , 2000, 57, 236-239.		9
59	Patterns of relapse and growth kinetics of surgery- and radiation-refractory meningiomas. <i>Journal of Neuro-Oncology</i> , 2015, 123, 151-160.	2.9	8
60	Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort. <i>Journal of Neuro-Oncology</i> , 2021, 153, 55-64.	2.9	8
61	Current Management of Large Vestibular Schwannomas for <scp>NF2</scp> Patients in a National Reference Center. <i>Laryngoscope</i> , 2021, 131, E98-E107.	2.0	7
62	NF2-Related Intravestibular Schwannomas: Long-Term Outcomes of Cochlear Implantation. <i>Otology and Neurotology</i> , 2020, 41, 94-99.	1.3	6
63	GAB1 overexpression identifies hedgehog-activated anterior skull base meningiomas. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 748-755.	3.2	6
64	Psychological follow-up care of neurofibromatosis type 2 patients and their relatives. <i>Neurochirurgie</i> , 2018, 64, 381-385.	1.2	5
65	Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas. <i>Journal of Neuro-Oncology</i> , 2017, 133, 633-639.	2.9	4
66	Objective improvement in adults with cerebellopontine angle arachnoid cysts after surgical treatment. <i>Acta Neurochirurgica</i> , 2021, 163, 753-758.	1.7	4
67	Intraoperative facial nerve electromyography parameters to optimize postoperative facial nerve outcome in patients with large unilateral vestibular schwannoma. <i>Acta Neurochirurgica</i> , 2021, 163, 2209-2217.	1.7	4
68	Sustained growth of intraosseous hormone-associated meningiomas after cessation of progestin therapy. <i>Acta Neurochirurgica</i> , 2021, 163, 1705-1710.	1.7	3
69	Neurofibromatosis type 2: A challenge for the neurosurgical medical community. <i>Neurochirurgie</i> , 2018, 64, 333-334.	1.2	2
70	Management of Neurofibromatosis Type 2 Associated Vestibular Schwannomas. <i>Current Otorhinolaryngology Reports</i> , 2021, 9, 170-176.	0.5	2
71	Hearing recovery after surgical resection of non-vestibular schwannoma cerebellopontine angle tumors. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, , 1.	1.6	2
72	An Overview of Meningiomas. , 2020, , 3-10.		1

#	ARTICLE	IF	CITATIONS
73	Long-term surgical oncological and functional outcome of large petroclival and cerebellopontine angle epidermoid cysts: a multicenter study. <i>Neurosurgical Review</i> , 2022, 45, 2119-2131.	2.4	1
74	Metachronous Bilateral Vestibular Schwannomas. <i>Laryngoscope</i> , 2021, 131, E250-E254.	2.0	0
75	OS12.7.A Characterization of intra-tumoral heterogeneity and differential immune activation during malignant progression of meningiomas on single cell level. <i>Neuro-Oncology</i> , 2021, 23, ii15-ii16.	1.2	0